Latest Biotech News

Roche moved to restart Europe-focused evidence for Duchenne muscular dystrophy gene therapy Elevidys by announcing a new global phase III trial. The study is designed to generate additional...

Eli Lilly reported positive cardiovascular safety results for its oral obesity and diabetes medicine Foundayo (orforglipron), meeting the main goal of a heart safety trial in a phase III program...

Revolution Medicines reported a survival advantage for its pan-RAS drug daraxonrasib in a global phase III study in metastatic pancreatic ductal adenocarcinoma. Patients treated with the daily...

UCB agreed to acquire Neurona in a deal valued at up to $1.2 billion, aiming to broaden its epilepsy portfolio beyond small molecules. UCB said the acquisition helps diversify into a potentially...

Neomorph secured a $100 million Series B round to advance its oral molecular glue degrader NEO-811 through clinical development and support broader pipeline progress. The company plans continued...

Storm Therapeutics raised $56 million in a Series C to fund phase II development of STC-15, an RNA enzyme inhibitor targeting METTL3-driven methylation pathways in selected sarcoma subtypes. The...

Foundation Medicine, a Roche subsidiary, agreed to buy Saga Diagnostics for up to $595 million, adding the company’s tumor-informed MRD platform Pathlight to Foundation’s test portfolio. The deal...

Biopharma continued to slow layoffs in the first quarter of 2026 compared with the prior year, but headcount reductions still climbed in aggregate due to large-company cuts. According to BioSpace...

UCB will buy Neurona in a deal valued at up to $1.2 billion, positioning the Belgian pharma to broaden beyond its small-molecule epilepsy portfolio with a potentially one-off cell therapy. The...

Revolution Medicines reported a landmark survival benefit for its investigational RAS-targeting drug daraxonrasib (RMC-6236) in a global Phase 3 trial in metastatic pancreatic ductal...

Roche said it will launch a new global Phase 3 trial for the Duchenne muscular dystrophy gene therapy Elevidys after Europe’s main regulator delivered a negative opinion. The company aims to...

Kailera Therapeutics priced an upsized U.S. IPO to raise about $625 million, setting a new benchmark for biotech listings. The obesity-focused company’s offering supports global development across...

Neomorph secured a $100 million Series B financing to advance NEO-811, an oral molecular glue degrader designed to induce targeted degradation of ARNT (HIF-1β). The company plans to use the...

Storm Therapeutics raised $56 million in a Series C financing to support Phase II development of STC-15, an RNA enzyme inhibitor targeting METTL3. The company said it has enrolled the first...

Roche subsidiary Foundation Medicine agreed to acquire Saga Diagnostics for up to $595 million, aiming to expand its oncology diagnostics portfolio in molecular residual disease (MRD). The deal...

Transformative Biotech unveiled extraction-free PCR chemistry designed to remove a key bottleneck in molecular testing workflows, targeting faster and cheaper infectious disease diagnostics. The...

Beeline Medicines launched with a portfolio of five programs licensed from Bristol Myers Squibb, supported by a $300 million Series A led by Bain Capital. The new company is developing afimetoran,...

Grifols said the U.S. FDA approved its Procleix Plasmodium assay for screening blood donors for malaria risk. The automated nucleic acid-based test detects ribosomal RNA sequences from multiple...

Eli Lilly’s oral obesity drug Foundayo cleared a key cardiovascular safety hurdle in people with type 2 diabetes, meeting a primary non-inferiority objective in a heart outcomes study versus...

Kailera Therapeutics raised $625 million in one of biotech’s biggest-ever initial public offerings, topping Moderna’s prior debut record. The Nasdaq offering funds Kailera’s obesity pipeline,...